Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q3 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the oil and gas industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table Of Contents

Partnerships, Licensing, Investments and MandA Deals and Trends in Pharmaceuticals - Q3 2013
Table of Contents

1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals and Healthcare, Global, Deal Summary, Q3 2013 15
2.1 Pharmaceuticals and Healthcare, Global, Deals Analysis, Q3 2013 15
2.2 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals, Q3 2013 17
2.3 Pharmaceuticals and Healthcare, Global, by Type, Deal Values, Q3 2013 18
2.4 Pharmaceuticals and Healthcare, Global, Top Deals, Q3 2013 19
2.4.1 Shoppers Drug Mart Receives Ontario Court Approval for Its Acquisition by Loblaw for US$11.93 Billion 19
2.4.2 Amgen Completes Tender Offer to Acquire Onyx Pharma for up To US$10.4 Billion 21
2.4.3 Community Health Systems to Acquire Health Management Associates for up to US$7.6 Billion 22
2.4.4 Fresenius to Acquire 43 Hospitals from Rhon-Klinikum for US$4.1 Billion 23
2.4.5 Tenet Healthcare Prices Private Placement of Notes Due 2022 for US$2.8 Billion 24
3 Pharmaceuticals and Healthcare, Global, Deals Summary, by Type 25
3.1 Pharmaceuticals and Healthcare, Global, MandA, Q3 2013 25
3.1.1 Top MandA Deals in Q3 2013 26
3.1.2 Pharmaceuticals and Healthcare, Global, MandA Deals, by Therapy Area, Q3 2012 - Q3 2013 27
3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Q3 2013 29
3.2.1 Top Initial Public Offerings in Q3 2013 31
3.2.2 Top Secondary Offerings in Q3 2013 31
3.2.3 Top PIPE Deals in Q3 2013 31
3.2.4 Pharmaceuticals and Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
3.2.5 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2012 - Q3 2013 33
3.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, Q3 2013 35
3.3.1 Top Venture Financing Deals in Q3 2013 36
3.3.2 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 37
3.3.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2013 38
3.3.4 Pharmaceuticals and Healthcare, Global, Venture Capital, by Therapy Area, Q3 2012 - Q3 2013 39
3.3.5 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 41
3.3.6 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, Q3 2012 - Q3 2013 43
3.4 Pharmaceuticals and Healthcare, Global, Private Equity Deals, Q3 2013 44
3.4.1 Top Private Equity Deals in Q3 2013 45
3.4.2 Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2012 - Q3 2013 46
4 Pharmaceuticals and Healthcare, Global, Partnership Deals, Q3 2013 48
4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, Q3 2013 48
4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2012 - Q3 2013 50
4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payments and Deal Values (US$ m), Q3 2013 52
4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2013 54
4.3.2 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
4.3.3 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2013 55
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 56
4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2012 - Q3 2013 58
4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2012 - Q3 2013 59
4.7 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 61
5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, Q3 2013 63
5.1 Pharmaceutical and Healthcare, Global, Licensing Agreements, Q3 2013 63
5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 65
5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2013 67
5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2013 67
5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2013 68
5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2012 - Q3 2013 69
5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 - Q3 2013 71
5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 - Q3 2013 73
5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2012 - Q3 2013 74
5.7 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2012 - Q3 2013 76
6 Pharmaceuticals and Healthcare, Global, MandA Financial Analysis 78
6.1 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2012 - Q3 2013 78
6.2 Pharmaceuticalsand Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2012 - Q3 2013 80
6.3 Pharmaceuticals and Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 82
6.4 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 - Q3 2013 84
6.5 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2012 - Q3 2013 86
6.6 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2012 - Q3 2013 88
6.7 Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 90
7 Pharmaceuticals and Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, Q3 2013 92
7.1.1 Oncology - Deals of the Quarter 94
7.2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, Q3 2013 96
7.2.1 Central Nervous System - Deals of the Quarter 98
7.3 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, Q3 2013 101
7.3.1 Infectious Disease - Deals of the Quarter 103
7.4 Pharmaceuticals and Healthcare, Global, Immunology Deals, Q3 2013 105
7.4.1 Immunology - Deals of the Quarter 107
7.5 Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals, Q3 2013 108
7.5.1 Metabolic Disorders - Deals of the Quarter 110
7.6 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, Q3 2013 112
7.6.1 Cardiovascular - Deals of the Quarter 114
7.7 Pharmaceuticals and Healthcare, Global, Gastrointestinal Deals, Q3 2013 116
7.7.1 Gastrointestinal - Deals of the Quarter 118
7.8 Pharmaceuticals and Healthcare, Global, Dermatology Deals, Q3 2013 119
7.8.1 Dermatology - Deals of the Quarter 121
7.9 Pharmaceuticals and Healthcare, Global, Respiratory Deals, Q3 2013 122
7.9.1 Respiratory - Deals of the Quarter 124
7.10 Pharmaceuticals and Healthcare, Global, Ophthalmology Deals, Q3 2013 126
7.10.1 Ophthalmology - Deals of the Quarter 128
8 Deal Summary by Geography 130
8.1 Pharmaceuticals and Healthcare, North America Region, Deals, Q3 2013 130
8.1.1 North America - Deals of the Quarter 132
8.2 Pharmaceuticals and Healthcare, Europe Region, Deals, Q3 2013 135
8.2.1 Europe - Deals of the Quarter 137
8.3 Pharmaceuticals and Healthcare, Asia-Pacific, Deals, Q3 2013 139
8.3.1 Asia-Pacific - Deals of the Quarter 141
8.4 Pharmaceuticals and Healthcare, Rest of the World, Deals, Q3 2013 144
8.4.1 Rest of the World - Deals of the Quarter 146
9 Pharmaceuticals and Healthcare, Global, Top Advisors 148
9.1 Pharmaceuticals and Healthcare, Global Top Financial Advisors, MandA, Last One Year 148
9.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 150
10 Appendix 152
11 Further Information 156
11.1 Methodology 156
11.2 About GlobalData 157
11.3 Disclosure information 158
11.4 Disclaimer 158



List of Tables

Table 1: Pharmaceuticals and Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 16
Table 2: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2013 19
Table 3: Pharmaceuticals and Healthcare, Global, Top Deals, Q3 2013 19
Table 4: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 26
Table 5: Pharmaceuticals and Healthcare, Global, Top MandA Deals, Q3 2013 26
Table 6: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2012 - Q3 2013 28
Table 7: Pharmaceuticals and Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 30
Table 8: Pharmaceuticals and Healthcare, Global, Top Initial Public Offering Deals, Q3 2013 31
Table 9: Pharmaceuticals and Healthcare, Global, Top Secondary Offering Deals, Q3 2013 31
Table 10: Pharmaceuticals and Healthcare, Global, Top PIPE Deals, Q3 2013 31
Table 11: Pharmaceuticals and Healthcare, Global, Top IPOs Share Performance, Q3 2012-Q3 2013 32
Table 12: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 34
Table 13: Pharmaceuticals and Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 36
Table 14: Pharmaceuticals and Healthcare, Global, Top Venture Capital Deals, Q3 2013 36
Table 15: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number of Deals and Deal Values (%), Q3 2013 38
Table 16: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 40
Table 17: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 42
Table 18: Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, Q3 2012 - Q3 2013 43
Table 19: Pharmaceuticals and Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 45
Table 20: Pharmaceuticals and Healthcare, Global, Top Private Equity Deals, Q3 2013 45
Table 21: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 47
Table 22: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 49
Table 23: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 51
Table 24: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 53
Table 25: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), Q3 2013 54
Table 26: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2013 54
Table 27: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2013 55
Table 28: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 57
Table 29: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 60
Table 30: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 62
Table 31: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 64
Table 32: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 66
Table 33: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2013 67
Table 34: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2013 67
Table 35: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2013 68
Table 36: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 70
Table 37: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment (US$ m), Q3 2012 - Q3 2013 72
Table 38: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 75
Table 39: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 77
Table 40: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2012 - Q3 2013 79
Table 41: Pharmaceuticals and Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2012 - Q3 2013 81
Table 42: Pharmaceuticals and Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 83
Table 43: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2012 - Q3 2013 85
Table 44: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2012 - Q3 2013 87
Table 45: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2012 - Q3 2013 89
Table 46: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 91
Table 47: Pharmaceuticals and Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 93
Table 48: Pharmaceuticals and Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 97
Table 49: Pharmaceuticals and Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 102
Table 50: Pharmaceuticals and Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 106
Table 51: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 109
Table 52: Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 113
Table 53: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 117
Table 54: Pharmaceuticals and Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 120
Table 55: Pharmaceuticals and Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 123
Table 56: Pharmaceuticals and Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 127
Table 57: Pharmaceuticals and Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 131
Table 58: Pharmaceuticals and Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 136
Table 59: Pharmaceuticals and Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 140
Table 60: Pharmaceuticals and Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 145
Table 61: Pharmaceuticals and Healthcare, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 149
Table 62: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 151
Table 63: Pharmaceuticals and Healthcare, Deals' Key Financials, Global Acquisition Deals, Q3 2012-Q3 2013 152

1.2 List of Figures
Figure 1: Pharmaceuticals and Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 15
Figure 2: Pharmaceuticals and Healthcare, Global, Number Of Deals (%), Q3 2013 17
Figure 3: Pharmaceuticals and Healthcare, Global, Deal Values (%), Q3 2013 18
Figure 4: Pharmaceuticals and Healthcare, Global, MandA, Number of Deals and Deal Values (US$m), Q3 2012 - Q3 2013 25
Figure 5: Pharmaceuticals and Healthcare, Global, MandAs, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2012 - Q3 2013 27
Figure 6: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 29
Figure 7: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2012 - Q3 2013 33
Figure 8: Pharmaceuticals and Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 35
Figure 9: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2013 37
Figure 10: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2013 38
Figure 11: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2012 - Q3 2013 39
Figure 12: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 41
Figure 13: Pharmaceuticals and Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 44
Figure 14: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2012 - Q3 2013 46
Figure 15: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 48
Figure 16: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 50
Figure 17: Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 52
Figure 18: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 56
Figure 19: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 58
Figure 20: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q3 2012 - Q3 2013 59
Figure 21: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payment and Deal Values (US$ m), Q3 2012 - Q3 2013 61
Figure 22: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 63
Figure 23: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Upfront and Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 65
Figure 24: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 69
Figure 25: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 71
Figure 26: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2012 - Q3 2013 73
Figure 27: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2012 - Q3 2013 74
Figure 28: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), Q3 2012 - Q3 2013 76
Figure 29: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2012 - Q3 2013 78
Figure 30: Pharmaceuticals and Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2012 - Q3 2013 80
Figure 31: Pharmaceuticals and Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2012 - Q3 2013 82
Figure 32: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2012 - Q3 2013 84
Figure 33: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2012 - Q3 2013 86
Figure 34: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2012 - Q3 2013 88
Figure 35: Pharmaceuticals and Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2012 - Q3 2013 90
Figure 36: Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 92
Figure 37: Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 96
Figure 38: Pharmaceuticals and Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 101
Figure 39: Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 105
Figure 40: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 108
Figure 41: Pharmaceuticals and Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 112
Figure 42: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 116
Figure 43: Pharmaceuticals and Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 119
Figure 44: Pharmaceuticals and Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 122
Figure 45: Pharmaceuticals and Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 126
Figure 46: Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 130
Figure 47: Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 135
Figure 48: Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 139
Figure 49: Pharmaceuticals and Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2012 - Q3 2013 144
Figure 50: Pharmaceuticals and Healthcare, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 148
Figure 51: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2012 - Q3 2013 150

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • February 2015
  • by Global Data

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 Summary Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, ...

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

  • $ 6 650
  • Industry report
  • May 2015
  • by BCC Research

This BCC Research study provides an in-depth analysis and forecast of selected areas of the global healthcare acquired infections (HAI) market. The report offers forecasts by treatment segment and type ...

Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency

Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency

  • $ 6 000
  • Industry report
  • April 2015
  • by Frost & Sullivan

Executive Summary Need for Effective Working Capital Management •Decreasing profitability •Fizzling innovation model •Access to new markets •Price premium pressure Key Trends •The analysis of ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.